Advancing Medicine. Precisely.

We have entered into two collaborations with Boehringer Ingelheim (“BI”).
We have entered into a discovery collaboration with Janssen Pharmaceuticals, Inc. (see press release) utilizing our XMarker microbiome-based biomarker discovery platform to stratify responders and non-responders to inflammatory bowel disease (IBD) therapeutics. XMarker applies a unique metagenomics-based approach to decipher full microbial genomic signatures that can be further developed into predictive biomarkers.

We have entered into two collaborations with Boehringer Ingelheim.

Our first collaboration with Boehringer Ingelheim was announced in September 2020 (see press release) utilizes the BiomX XMarker microbiome-based biomarker discovery platform to potentially identify biomarkers associated with patient phenotypes in inflammatory bowel disease. The terms of the collaboration include an option for Boehringer Ingelheim to negotiate an exclusive right to biomarkers discovered utilizing the XMarker platform.

Our Second collaboration with BI announced in June 2022 (See press release) utilizes our XMarker platform to potentially identify biomarkers for a pathogenic bacterium thought to be associated with inflammatory bowel disease. Such biomarkers could help identify IBD patients that would benefit from potential therapies targeted at the microbiome.
The terms of the collaboration entitle us to research payments and also include an option for Boehringer Ingelheim to negotiate an exclusive right to biomarkers discovered under the collaboration.

We have entered into an agreement granting Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, a right of first offer to license our atopic dermatitis product candidate, BX005, in Japan. Maruho also entered into a binding agreement for an equity investment in the company, intended primarily to support the Phase 1/2 study of BX005